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USING N-OF-1 TRIALS TO IMPROVE PATIENT MANAGEMENT 
AND SAVE COSTS 
 
ABSTRACT 
Background:  N-of-1 trials test treatment effectiveness within an individual patient.  
Objective: To assess (i) the impact of 3 different N-of-1 trials on both clinical and economic 
outcomes over 12-months and (ii) whether the use of N-of-1 trials to target 
patients’ access to high-cost drugs might be cost-effective in Australia.   
Design: Descriptive study of management change, persistence, and costs summarizing 
three N-of-1 trials 
Participants: Volunteer patients with osteoarthritis, chronic neuropathic pain or ADHD whose 
optimal choice of treatment was uncertain 
Interventions: Double-blind cyclical alternative medications for the three conditions 
Measures:  Detailed resource use, treatment and health outcomes (response) data collected by 
postal and telephone surveys immediately before and after the trial and at 3, 6 and 
12-months.  Estimated costs to the Australian healthcare system for the pre-trial vs 
12-months post-trial.  
Results: Participants persisting with the joint patient-doctor decision 12-months after trial 
completion were 32% for osteoarthritis, 45% for chronic neuropathic pain and 
70% for the ADHD trials.  Cost-offsets were obtained from reduced usage of non-
optimal drugs, and reduced medical consultations.  Drug costs increased for the 
chronic neuropathic pain and ADHD trials due to many patients being on either 
low-cost or no pharmaceuticals before the trial.    
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Conclusions: N-of-1 trials are an effective method to identify optimal treatment in patients in 
whom disease management is uncertain.  Using this evidence-based approach, 
patients and doctors tend to persist with optimal treatment resulting in cost-
savings.  N-of-1 trials are clinically acceptable and may be an effective way of 
rationally prescribing some expensive long-term medicines.   
 
Keywords: N-of-1 trials, cost-effectiveness, follow-up study, rational prescribing 
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BACKGROUND 
Chronic diseases are now among the most prevalent and costly of all health 
problems.1  A large proportion of health costs are attributable to pharmaceuticals.2  These 
costs would be reduced by targeting drugs just to patients who benefit from them.  The 
present open-access model means patients who opt for expensive treatments may well be 
effectively managed with a less expensive treatment.  Conversely, denying access to higher 
cost pharmaceuticals because of an unfavorable average cost-benefit ratio will deny access 
for a sub-group of patients who would receive large incremental benefits from treatment, and 
for whom the treatment would be cost-effective.  This is particularly important for conditions 
in which individual responses to a treatment are variable.  
 
N-of-1 trials are multi-cycle within-patient, randomized, double-blind, cross-over 
comparisons of a drug and placebo (or another drug) using standardized measures of effect 
(Figure 1). They provide evidence-based information on individual response to treatment and 
can be used to optimize the chronic disease management of the individual in the trial.  
 
Essential characteristics of medicines suitable for the conduct of an n-of-1 trial are: 1) 
the condition for which the medication is being prescribed is chronic and [relatively] stable; 
2) the half-life of the medication being tested is short; 3) there is rapid onset/offset of 
biological action of the medication; 4) the effect of the medication can be measured using a 
validated outcome measure; 5) the medication does not alter the underlying condition.3, 4 
 
Clinicians commonly conduct informal trials of therapy when they start a drug in a 
patient and judge the clinical response. However, compared with the more structured N-of-1 
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trials, these are methodologically inadequate to provide evidenced-based information for 
tailoring the individual’s chronic disease management.  Although N-of-1 trials are not widely 
used, there is potential for these to become part of normal medical practice for targeted 
illnesses, drugs and participants.5, 6 Moreover, N-of-1 trials may facilitate targeting of 
government subsidized medicines to patients for whom there is demonstrable benefit.7 
 
Objectives 
The objective of the study is to determine if the use N-of-1 trials reduces health care 
costs compared to “standard practice”.  We summarize here the impact of three N-of-1 trials 
including a one-year follow-up. This follow-up was important to monitor adherence to the 
optimized therapy identified in the trial and observe the associated costs.  We report the 
observed costs of management and the expected costs for scenarios where the higher-cost 
pharmaceuticals are restricted to responders only.   
 
METHODS 
Design 
In 2003-5, we conducted three N-of-1 trials:  
(i) Celecoxib (Celebrex) versus sustained release acetaminophen (SR-acetaminophen) 
(PanadolOsteo) for osteoarthritis performed in a community setting  
(ii) Gabapentin (Gantin) versus placebo for chronic neuropathic pain performed mostly in 
a hospital outpatient setting and  
(iii) Dexamphetamine (dexamphetamine sulfate) versus methylphenidate (Ritalin/Ritalin 
LA) or placebo for ADHD performed in both a community and a hospital outpatient setting.  
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 Ethics approval for the trials was obtained from The University of Queensland’s 
Medical Research Ethics Committee. Additionally, for the neuropathic pain trial, approval 
was obtained from the ethics committees of the participating institutions, Princess Alexandra 
Hospital, Brisbane and the Port Kembla Hospital, Port Kembla. For the ADHD trial, 
additional approval was obtained from the ethics committee of Mater Misericordiae Health 
Services, Brisbane. In late 2004, the Australian Therapeutic Goods Administration instructed 
all trials using celecoxib to cease due to possible adverse health events identified in other 
members of the selective COX-2 inhibitor class of drugs, and recruitment for this trial was 
ceased prematurely. 
 
Participants 
Participants were volunteer patients with osteoarthritis, chronic neuropathic pain or 
ADHD whose optimal choice of treatment was uncertain. The trial methods have been 
described elsewhere and are summarized in Table 1.8-10    
 
  TABLE 1 ABOUT HERE 
  FIGURE 1 ABOUT HERE 
 
Outcomes data 
 For this study, a pre-post trial design was used to compare participants’ use of 
medications before and after the N-of-1 trial.  On completion of the trials participants were 
classified as “responders” and “non-responders”; at this time a management plan was agreed 
between the participant and their clinician (see Table 1).  Follow-up semi-structured 
telephone interviews were conducted at three, six and 12-months for all participants who 
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completed the trials.  These interviews recorded information on the participant’s current 
therapeutic management, reasons for any changes in treatment strategy, and feedback about 
the impact of the trial on the management of the participant’s symptoms. This information 
was used to determine the effects of the N-of-1 trial on individuals’ disease management.   
 
Economic analysis  
The present study focuses on responders and non-responders as classified at the end 
of the trial.  For this analysis, cases with complete records were used; cases identified as 
possible responders were classified as non-responders. 
 
A cost analysis took the perspective of costs to the Australian healthcare system.  
These are costs associated with management of osteoarthritis, chronic neuropathic pain and 
ADHD largely incurred through visits to primary care physicians, specialists in hospital 
outpatients, and for pharmaceuticals. Allied health costs (e.g. physiotherapy) were not 
considered in the analysis. 
 
Costs for these healthcare services are borne by the federal government through the 
PBS and Medicare for primary care physician visits, and by State governments for public 
hospital outpatient services.  Co-payments and out-of-pocket expenses incurred by patients 
were not included. 
 
Data collected from participants included details of treatments and disease 
management strategies for the three months before the N-of-1 trial (pre-trial data), data on 
resource use to 12-months follow-up and the fixed and variable costs of administering the 
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trials. Participants were asked the number of visits to the doctor and details on 
pharmaceutical use at that time.  These resources were assigned a standard cost of $31.45 per 
General Practitioner (GP; i.e. family physician) visit and $65.40 per specialist visit (the 
amount rebated to the patient by Medicare for a primary care visit or a specialist follow-up 
visit;11 A$1 ≈ US$0.70); pharmaceuticals were assigned the full price from the Schedule of 
Pharmaceutical Benefits.12   
 
Three scenarios are analyzed (Figure 2).  First is the observed pre- and post-trial costs 
for the participants in the three trials, including costs for pharmaceuticals and medical 
consultations.  In the second scenario, we assumed continuing access to the pharmaceutical in 
question is dependent on evidence of a response to the pharmaceutical from the N-of-1 trial 
(i.e. only responders to the higher cost pharmaceutical would be eligible to receive it).  We 
used the observed pre- and post-trial medical consultation rates and calculated the expected 
costs for restricting the higher-cost pharmaceuticals to responders.  In the third scenario, we 
assumed that all participants had been using the higher cost pharmaceutical for at least three 
months prior to entry into the trial, and only responders to the higher cost pharmaceutical 
would eligible to continue to receive that pharmaceutical.  This scenario is an extension of the 
second scenario to model the expected costs and consequences for patients who are using the 
pharmaceutical prior to commencing the N-of-1 trial.  
 
 FIGURE 2 ABOUT HERE 
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The healthcare use and costs in the previous three months reported in the post-trial 
surveys at months three, six and 12 were used to estimate annual totals; the costs and 
healthcare use reported at the 12 month surveys for the previous three months was doubled to 
give a six month estimate.  The reported pre-trial data were extrapolated to 12-months (by 
multiplying these costs by four).  Differences in pre- and post-trial costs for the three 
scenarios were then calculated.  
 
Data were analyzed using Excel and SPSS version 17.  Means, medians, SDs and 
inter-quartile ranges (IQRs) are presented for descriptive statistics.  In addition, the 
percentage of participants with a reduction in health care use, pharmaceuticals or costs in the 
post-trial period are reported. 
 
To calculate the significance of mean differences between costs in the pre- and post-
trial periods, t-tests were used.  However, small sample sizes and differenced data are more 
likely to be non-normally distributed.  Therefore, each series of differenced data were 
randomly resampled 10,000 times (i.e. bootstrapped) with the bias-corrected and accelerated 
(BCa) method.13, 14  This enabled normalized 95% confidence intervals (95%CI) to be 
estimated and t-tests to be conducted.  A statistically significant difference was defined as a 
probability of 5% or less that the result occurred by chance.  
 
RESULTS 
The demographic and clinical characteristics of the participants in each of the three 
trials have been described previously and are summarized in Table 2.  
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TABLE 2 ABOUT HERE 
 
All participants in the osteoarthritis trials completed all pre- and post-trial surveys; 
however, the proportions completing all surveys in the neuropathic pain and ADHD trials 
were lower.  We had no way of determining any bias for those who were lost to follow-up, 
and therefore restricted the analysis to only those completing all surveys.  The ADHD trial 
had enrolled a substantial number of participants without obtaining pre-trial data because it 
had already commenced when funding for this current study was received. 
 
The N-of-1 trials included identification of changes to patient management at the end 
of the trials and compliance with the clinical decision over the following 12-months. These 
results have been described in detail elsewhere and are summarized in Table 2.8-10, 15  The 
rates of persistence with the treatment decision from the trial at 12-months were greatest for 
ADHD participants at approximately 70% followed by 45% for celecoxib participants and 
32% of the participants from the neuropathic pain trial.  The persistence rate in the celecoxib 
trial may have been reduced by well-publicized warnings published in the media and 
understandable anxiety.    
 
The annual mean number of medical consultations was lower in the post-trial period 
than the pre-trial period for all three trials, with 5.9, 5.0 and 2.2 fewer consultations in the 
osteoarthritis, neuropathic pain, and ADHD trials respectively (Table 3).  These differences 
were statistically significant in the osteoarthritis trial (p<0.001), but not in the neuropathic 
pain trial (p=0.076) nor the ADHD trial.   
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TABLE 3 ABOUT HERE 
 
In all three trials, fewer pharmaceuticals were prescribed in the post-trial compared 
with the pre-trial period; these differences were not significant.  However, the smaller 
number of items prescribed resulted in pharmaceutical costs that were significantly lower in 
the osteoarthritis trials only (A$72, p=0.045).  Significantly higher mean costs for 
pharmaceuticals were noted in the neuropathic pain trials (A$468; p=0.011) and no 
significant difference in the ADHD trials (A$32; p=0.212) (Table 3).  
 
Following the osteoarthritis and neuropathic pain trials, the annual costs to the health 
system were significantly lower than the pre-trial period (i.e. cost-saving), and lower, but not 
significantly, (-A$37; p=0.558) following the ADHD trials. These differences in total costs 
are largely due to the costs saved from lower medical consultation rates in the post-trial 
period. (Table 3).  
 
The N-of-1 trials for osteoarthritis were most likely to result in cost-savings; (i.e. 
following these trials, cost-savings to the health system were obtained for 75.6% of the 
participants).  In the neuropathic pain trials, cost-savings to the health system were obtained 
for 60.6% of participants whereas in the ADHD trials, cost-savings were obtained for 44.4% 
(Table 3).  
 
Scenario Analyses – Trial results endorsed and prior use of higher costs pharmaceuticals 
Results for the scenarios where evidence is required for continued access to the 
pharmaceutical in question are reported in Table 4.  When trial results are endorsed, the costs 
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of pharmaceuticals are cost-saving for osteoarthritis (and of similar magnitude as those 
observed – see Table 3), but continue to result in higher costs for neuropathic pain and 
ADHD.  However, compared with the observed costs (Table 3), the costs for pharmaceuticals 
in the neuropathic pain and ADHD trials are substantially lower when trial results are 
endorsed.  Under this scenario, N-of-1 trials result in statistically significant cost-savings to 
the health system for osteoarthritis and neuropathic pain (p<0.001 for both), but no 
statistically significant difference in the ADHD trials.  When all participants were assumed to 
have used the higher cost pharmaceutical for the three months before the trials, significant 
cost-savings to the health system were evident for all three trials (Table 4).   
 
TABLE 4 ABOUT HERE 
 
DISCUSSION 
 The N-of-1 trials for osteoarthritis, chronic neuropathic pain and ADHD appeared to 
have a high impact on prescribing with a high proportion of management changes compared 
to baseline over the 12-months of follow-up.9, 10, 15, 16  In addition, persistence was high for 
the ADHD trial (70%).  Indeed, another methylphenidate N-of-1 study has shown >80% 
persistence with the joint decision at similar time periods.16  However, persistence was lower 
with the osteoarthritis and chronic neuropathic pain trials (45% and 32%). For the celecoxib 
trial, persistence decreased substantially to about a third of participants after ceasing the trial 
prematurely due the warnings in the media about COX-2 inhibitors.  This rate is similar to 
general compliance rates reported in the literature for participants who have not been 
involved in N-of-1 trials.17, 18  
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 Comparing the costs for pharmaceuticals and medical consultations for the 12-months 
pre- and post the N-of-1 trials, significant cost-savings to the health system were evident for 
the osteoarthritis and chronic neuropathic pain trials.  The majority of cost-savings were from 
reductions in medical consultations rather than reduced pharmaceutical costs.  In fact, the 
pharmaceutical costs for the chronic neuropathic pain trials and the ADHD trials increased 
following the trial due to many patients being on low-cost pharmaceuticals before the trial, 
and those showing a response to the higher cost pharmaceutical in the trials continued with 
the higher cost pharmaceutical after the trial.  In the absence of an N-of-1 trial, these patients 
would have commenced higher cost pharmaceuticals with an uncertain response, and incurred 
higher costs than our estimates.   
 
The costs reported above do not include the costs of running the trial.  We estimate 
the marginal costs were approximately $600 per participant in each trial. The marginal cost 
includes recruitment, preparation and dispatch of pharmaceutical packs, data collection and 
analysis, generation of results, and feedback of results and follow-up for 12-months.  In 
practice, active recruitment, 3, 6 and 12-month follow-up is not required outside of a research 
agenda; therefore, the marginal costs will be limited to dispatch and retrieval of medications, 
data entry and report generation with a marginal cost of approximately $100.  However, there 
are substantial fixed costs including design of protocols, questionnaires, database and 
pharmaceutical packs that are independent of the number of participants.  The total fixed cost 
for the three N-of-1 trials in the research setting was close to $70,000 ($350 per participant) 
but estimate these to be close to $9000 per trial in practice as greater efficiencies and 
economies of scale develop.  Overall, the resources required for N-of-1 trials are relatively 
few to reduce therapeutic uncertainty.19 
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N-of-1 trials are most applicable when the use of more expensive agents are restricted to 
those patients who have tried and failed less expensive agents in the same therapeutic class.  
Treatment algorithms imposed by the funder (in Australia, the PBS) might specify that an N-of-1 
trial must be undertaken to prove effectiveness in that patient; only when evidence of response is 
determined may the patient gain subsidized access  to high cost therapy.  Since all patients in this 
study had an uncertain response to treatment before the N-of-1 trial, the trial allowed 
identification of responders and non-responders.  These N-of-1 trials indicate that many of these 
patients have no incremental benefit from the more expensive agent, and the cost-savings from 
identifying responders and non-responders can in some cases justify the cost of undertaking the 
N-of-1 trial.  Furthermore, the potential to identify non-responders and avoid unnecessary 
exposure to both the risks and costs of ineffective treatment should not be underestimated.  Some 
centers routinely use N-of-1 trials in clinical practice, for example some cystic fibrosis centers 
have developed N-of-1 trials of rhDNase.20
 There are several limitations of these three studies.  In this analysis, outcomes were 
dichotomized as responder or non-responder.  This was a pragmatic approach given the 
relatively small numbers in the trials.  However, some patients had a partial response where 
they may have reported a positive response in one or two of the three cycles.  Therefore, 
prespecified thresholds for determining response should be developed prior to any N-of-1 
trial.  In this study, our responder threshold was a positive response in all three cycles.  In 
practice, a clinician must make a binary decision about whether the patient should continue 
with the pharmaceutical or not.  Therefore, if N-of-1 trials are to be used in practice, the 
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definition of a responder should be developed that is specific to the pharmaceutical. In 
addition, the costs of the trials  
  
 It is possible that reductions in costs from the pre-trial to post-trial periods were 
exaggerated by the ‘regression to the mean’ phenomenon where people may be motivated to 
join trials when their problem is at its worst, making spontaneous improvement more likely.21 
In the absence of a control group, we are not able to estimate the effect of this phenomenon, 
but the same phenomenon may be a factor with patients seeking care outside of trial settings.  
 
 The rate of loss to follow-up is acceptable,16, 22 although it may be considered the 
greatest limitation of the study.  Persistence rates with the treatment decision from the trial at 
12-months were greatest for ADHD participants at approximately 70% followed by 45% for 
celecoxib participants and 32% of the participants from the neuropathic pain trial.  Although 
not conclusive because of the lack of a control group, our results point towards a potential 
improvement in persistence after completing an N-of-1 trial, at least for ADHD.  This finding 
is worth further study considering the difficulties with pharmaceutical–taking in many 
chronic conditions.  
  
N-of-1 trials such as those reported here, represent the highest standards of 
establishing therapeutic benefits and harms in an individual.23, 24  These trials not only 
account for patient perceptions and values, but patients are more likely to become compliant 
and adhere better to their treatment regimen, gain greater understanding of their disease and 
their treatment regimen, and improve the relationship with their healthcare professional.25  
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CONCLUSION 
 This study shows that using N-of-1 trials to identify optimal treatment led to patients 
and their doctors tending to persist with that treatment.  Implementation of a large scale N-of-
1 trials program would need to balance the perceived clinical benefits against the net costs of 
implementation, but may be worthwhile when there is uncertainty about individual response 
to high cost pharmaceuticals.   
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LIST OF ABBREVIATIONS 
 
ADHD attention-deficit hyperactivity disorder  
 
BCa   bias-corrected and accelerated  
 
GP  General Practitioner i.e. family physician  
 
IQR  inter-quartile range  
 
OA  osteoarthritis  
 
PBS  Pharmaceutical Benefits Scheme  
 
RCT  randomized controlled trial  
 
SD  standard deviation  
 
SR slow-release  
 
95% CI  95% confidence interval  
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LEGENDS 
Figure 1. Typical N-of-1 trial. The order of treatment and placebo are randomly assigned for 
each cycle  
 
Figure 2. Scenarios evaluated for use of higher cost pharmaceuticals  
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Table 1.  Methods summary for the three N-of-1 trials. 
Chronic 
disease 
Treatment and 
Comparator  
Structure of trial Outcome measures 
Osteo-
arthritis  
Celecoxib and 
Sustained-
release (SR) 
acetaminophen 
 12 week total   
 3 x 4-week 
cycles  
 each cycle was 
2 weeks on 
each 
pharmaceutical.  
Pain, stiffness, functional limitation, 
frequency of adverse events and 
preferred pharmaceutical.  
Differential responses in pain, stiffness 
and functional limitation responses 
were determined by minimum clinically 
detectable differences; for adverse 
events, by a lower frequency on one 
pharmaceutical in at least two cycles; 
and preferred pharmaceutical by a 
preference for one pharmaceutical in at 
least two cycles. These variables were 
then equally weighted to determine the 
overall response status of each 
participant. 
 
Chronic 
neuropath
ic pain 
Gabapentin 
and Placebo 
 12 week total  
 3 x 4-week 
cycles  
 each cycle was 
2 weeks on 
gabapentin or 2 
weeks on 
placebo. 
Pain, sleep interference, functional 
limitation, frequency of adverse events 
and preferred pharmaceutical.  
Differential responses in pain, sleep 
interference and functional limitation 
responses were determined by 
minimum clinically detectable 
differences; for adverse events, by a 
lower frequency on one pharmaceutical 
in at least two cycles; and preferred 
pharmaceutical by a preference for one 
pharmaceutical in at least two cycles. 
These variables were then equally 
weighted to determine the overall 
response status of each participant. 
 
ADHD Methylphenidat
e LA and 
Dexamphetami
ne 
 3 week total  
 3 x 5-day cycles  
 two days on 
each 
pharmaceutical 
separated by 
one washout 
day, and a two-
day washout 
period at the 
weekend.  
Responders  
Responders defined as those who had 
an improvement in symptoms, reported 
by their parent, with one treatment over 
the other in all three cycles.  
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Table 2.  Summary demographics and participant characteristics of the three N-of-1 trials. 
 
  Neuropathic pain 
trials 9 a 
Osteoarthritis 
trials 10 a 
ADHD trials 26 a 
Number enrolled in 
trial, N (% completed 
N-of-1 trial) 
73 (75%) 59 (69%) 86 (88%)  
Age in years - 
median (min, max) 
58 (24, 94) 65 (47, 80) 10 (5, 16)  
Sex (% male) 33% 37% 74%  
Prior treatment    
Years (mean, SD) 6.6 (8.5) 11.3 (10.3) 5.1 (4.3)  
   range (min, max) 0.8, 40 1, 46 0.7, 12 
Pre-trial main 
regular 
pharmaceuticals 
Gabapentin (16%) NSAID alone 
(56%) 
Methylphenidate 
(42%)  
 Acetaminophen (15%) NSAID with SR 
acetaminophen 
(17%) 
Dexamphetamine 
(55%)  
 Acetaminophen 
with codeine 
(11%) 
No 
pharmaceuticals 
(15%) 
No 
pharmaceuticals 
(3%)  
 No 
pharmaceuticals 
(13%) 
Other (12%)  
  NSAIDs (7%)     
Pharmaceuticals in 
N-of-1 trials 
Gabapentin vs 
placebo 
Celecoxib vs SR-
acetaminophen 
Methylphenidate / 
Dexamphetamine 
vs placebo 
Key clinical results Gabapentin was 
more effective 
than placebo in 
29% of 
participants, in 2% 
placebo was better 
and in 69% there 
was no difference  
Celecoxib was 
more effective 
than SR 
acetaminophen for 
17% of 
participants; 
SR 
acetaminophen 
was the most 
effective for 2% 
and in 80% there 
was no difference 
Treatment with 
stimulants was 
definitely more 
effective than 
placebo for 42% of 
66 completers, 
possibly in 17% 
and definitely not 
in 41%. 
Number with 
complete pre-trial 
and 12-month 
follow-up data (n) b 
41 32 18 
Persistence with 
trial decision at 12-
months (%) b 
31.7% 44.9% 69.8% 
Mean cost of 
active 
pharmaceutical in 
trials (A$) c 
$106.24 $29.91 / $11.69 $17.76 / $16.53 
Quantity 
dispensed 
100 x 300mg tabs  30 x 200mg tabs / 
192 x 665mg tabs 
100 x 10mg tabs / 
100 x 5mg tabs 
 26 
Mean daily dose of 
active 
pharmaceuticals 
(mg) 
1317mg 244mg / 3990mg 32.4mg / 17.7mg 
a  Data reported for completers unless otherwise stated  
b. Data pertaining to current analysis  
c. Excludes dispensing fees 
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Table 3. Observed costs and potential cost-savings in the three N-of-1 trials. 
 Annual estimates 
Mean difference 
95% CI's  Participants with 
reduced 
healthcare use 
or cost-savings  pre-trial post-trial Lower Upper p-value 
Osteoarthritis trials (Celecoxib vs 
acetaminophen; N=41)        
Mean medical consultations (n) 13.95 8.08 -5.87 -9.32 -2.51 0.0007 70.7% 
Mean prescription items (n) 19.61 17.85 -1.76 -4.02 0.29 0.1108 43.9% 
Mean cost medical consultations (A$) 438.77 252.37 -186.40 -293.02 -80.54 0.0006 70.7% 
Mean cost prescription items (A$) 428.87 356.62 -72.26 -144.03 -2.68 0.0451 56.1% 
Mean (SD) health system cost (A$) 867.64 608.99 -258.65 -395.35 -123.25 0.0002 75.6% 
 (440.27) (255.91) (448.79)     
Median (Q1; Q3) health system cost (A$) 813.76 568.42 -189.81     
 (657.40; 952.32) (434.45; 737.75) (-494.78; -1.29)     
Neuropathic pain trials (Gabapentin vs placebo; 
N=32)        
Mean medical consultations (n) 19.41 14.44 -4.97 -10.44 0.53 0.0757 58.8% 
Mean prescription items (n) 7.53 7.15 -0.38 -2.32 1.47 0.6928 47.1% 
Mean cost medical consultations (A$) 1407.50 454.18 -953.33 -1166.08 -745.20 <0.0001 91.2% 
Mean cost prescription items (A$) 726.97 1145.52 418.55 99.75 742.85 0.0107 37.1% 
Mean (SD) health system cost (A$) 2143.35 1675.73 -467.63 -903.44 -45.78 0.0326 60.6% 
 (999.20) (1117.30) (1300.53)     
Median (Q1; Q3) health system cost (A$) 1950.58 1753.12 -551.76     
 
(1494.62; 
2513.87) 
(707.30; 
2304.92) (-1211.18; 440.62)     
ADHD trials (Stimulants vs placebo; N=18)        
Mean medical consultations (n) 6.00 3.78 -2.22 -5.61 0.94 0.1839 44.4% 
Mean prescription items (n) 3.11 2.11 -1.00 -2.67 0.44 0.2077 38.9% 
Mean cost medical consultations (A$) 188.70 118.81 -69.89 -174.72 31.45 0.1839 44.4% 
Mean cost prescription items (A$) 89.64 122.16 32.51 -18.90 83.15 0.2117 33.3% 
Mean (SD) health system cost (A$) 278.34 240.97 -37.38 -166.03 83.85 0.5577 44.4% 
 (343.65) (199.07) (282.08)     
Median (Q1; Q3) health system cost (A$) 217.44 220.63 7.65     
 (100.18; 218.58) (102.57; 303.84) (-150.71; 86.40)     
* includes specialist visits: pre-trial mean = 2.18, 3-month post-trial mean = 1.0; these specialist visits were excluded from the statistical tests 
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Table 4.  Scenarios with pharmaceutical access dependant on results of N-of-1 trials. 
         Annual estimates  95% CI's  Participants 
with 
reduced 
healthcare 
use or cost-
savings   
                 pre-
trial post-trial 
Mean 
difference Lower Upper p-value 
Osteoarthritis trial (Celecoxib vs placebo)       
N-of-1 trial results endorsed        
 Mean cost medical consultations (A$) 438.77 252.37 -186.40 -293.02 -80.54 0.0006 70.7% 
 Mean cost prescription items (A$) 428.87 357.44 -71.44 -137.65 -5.51 0.0341 48.8% 
 Mean (SD) health system cost (A$) 867.64 609.80 -257.84 -384.17 -138.13 <0.0001 75.6% 
  (440.27) (256.78) (413.19)     
All patients on Celecoxib 3/12 pre-trial and trial results endorsed      
 Mean cost medical consultations (A$) 438.77 252.37 -186.40 -293.02 -80.54 0.0006 70.7% 
 Mean cost prescription items (A$) 459.24 357.44 -101.81 -167.90 -36.27 0.0024 61.0% 
 Mean (SD) health system cost (A$) 898.01 609.80 -288.20 -412.04 -163.58 <0.0001 80.5% 
  (419.61) (256.78) (418.03)     
Neuropathic pain trial (Gabapentin vs placebo)       
N-of-1 trial results endorsed        
 Mean cost medical consultations (A$) 1407.50 454.18 -953.33 -1166.08 -745.20 <0.0001 91.2% 
 Mean cost prescription items (A$) 726.97 811.08 84.11 -245.69 418.77 0.6198 51.4% 
 Mean (SD) health system cost (A$) 2094.26 1252.28 -841.98 -1230.29 -477.28 <0.0001 79.4% 
  (911.80) (859.19) (1129.94)     
All patients on Gabapentin 3/12 pre-trial and trial results endorsed      
 Mean cost medical consultations (A$) 1407.50 454.18 -953.33 -1166.08 -745.20 <0.0001 91.2% 
 Mean cost prescription items (A$) 999.44 811.08 -188.36 -516.51 137.56 0.2590 65.7% 
 Mean (SD) health system cost (A$) 2366.73 1252.28 -1114.45 -1512.67 -752.49 <0.0001 85.3% 
  (909.00) (859.19) (1124.66)     
ADHD trial (Stimulants vs placebo)        
N-of-1 trial results endorsed        
 Mean cost medical consultations (A$) 188.70 118.81 -69.89 -174.72 31.45 0.1839 44.4% 
 Mean cost prescription items (A$) 89.64 74.36 -15.29 -68.69 38.24 0.5753 55.6% 
 Mean (SD) health system cost (A$) 278.34 193.17 -85.17 -203.11 29.40 0.1510 50.0% 
  (343.65) (170.81) (265.08)     
All patients on high-cost medications pre-trial and trial results endorsed      
 Mean cost medical consultations (A$) 188.70 118.81 -69.89 -174.72 31.45 0.1839 44.4% 
 29 
 Mean cost prescription items (A$) 123.05 74.36 -48.70 -93.91 -2.37 0.0371 72.2% 
 Mean (SD) health system cost (A$) 311.75 193.17 -118.58 -234.19 -12.99 0.0356 66.7% 
  (324.09) (170.81) (248.68)     
 
 
 
 
  
 30 
FIGURES 
 
Figure 1. Typical N-of-1 trial. The order of treatment and placebo are randomly assigned for each cycle  
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Figure 2. Scenarios evaluated for use of higher cost pharmaceuticals  
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